Notice of Proposed Sale · 144
Editas Medicine, Inc.
EDITNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Editas Medicine, Inc.
- Issuer CIK
- 0001650664
- SEC file number
- 001-37687
- Phone
- 617-401-9000
- Person for whose account securities are to be sold
- Burkly Linda
- Relationships to issuer
- Officer
- Street
- 11 HURLEY ST.
- City
- CAMBRIDGE
- State / country code
- MA
- Postal code
- 02141
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common Stock | 700 | 2,296.00 | 153,580,035 | 09/03/2026 | NASDAQ | ETrade Corporation |
Broker / market maker — proposed row 1, entry 1
- Name
- ETrade Corporation
- Street
- 3 Edison Financial
- City
- Alphareta
- State / country code
- GA
- Postal code
- 30005
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common Stock | 09/02/2026 | Restricted Stock Unit Vesting | Issuer | 1,550 | N | 09/02/2026 | Equity Compensation |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Linda C. Burkly | Common Stock | 06/03/2026 | 731 | 1,974.50 |
| Linda C. Burkly | Common Stock | 07/28/2026 | 4,928 | 13,157.76 |
Seller — prior-sale row 1, entry 1
- Name
- Linda C. Burkly
- Street
- 11 Hurley Street
- City
- Cambridge
- State / country code
- MA
- Postal code
- 02141
Seller — prior-sale row 2, entry 1
- Name
- Linda C. Burkly
- Street
- 11 Hurley Street
- City
- Cambridge
- State / country code
- MA
- Postal code
- 02141
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/31/2026
- Signed
- /s/ Linda C. Burkly
- Plan adoption dates
- 07/03/2023
Company context
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of CRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines.